Drugs / Plamotamab
Plamotamab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07230353 | Oct 2025 → Jun 2028 expected | rheumatoid arthritis | Xencor, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT02924402 | Oct 2016 → Apr 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Xencor, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05328102 | Apr 2022 → Feb 2023 | diffuse large B-cell lymphoma | Xencor, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2022-12-12 | Xencor, Inc. | Results Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting xencor.com ↗
In the Phase 1 monotherapy study of plamotamab, the recommended intravenous dose was well tolerated, and we are encouraged by the responses observed in the study. |
| 2022-11-03 | Xencor, Inc. | Results Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting xencor.com ↗ |
| 2021-12-12 | Xencor, Inc. | Results Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting xencor.com ↗
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell non-Hodgkin lymphomas. |
| 2021-11-04 | Xencor, Inc. | Results Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting xencor.com ↗
After the implementation of higher doses in the flat-dosing regimen, the ORR among all patients with NHL had improved to 50% (4/8) from 42.2% (19/45) in prior weight-based dosing cohorts. |
| 2019-12-09 | Xencor, Inc. | Results Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting xencor.com ↗
XmAb13676 has been generally well tolerated and has demonstrated encouraging clinical activity in patients with advanced non-Hodgkin’s lymphoma as a monotherapy in initial dose escalation cohorts. |
| 2019-11-06 | Xencor, Inc. | Results Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting xencor.com ↗
Initial results from dose-escalation cohorts demonstrate encouraging clinical activity in heavily pretreated patients with several subtypes of non-Hodgkin lymphoma, as well as chronic lymphocytic leukemia. |
All press releases naming this drug 8 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plamotamab | “Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies” NCT02924402 ↗ |
| Known as | XENP13676 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298130 ↗ |
| Known as | XmAb13676 | “The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously...” NCT07230353 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4298130 ↗ |
| Route | Intravenous | “intravenous (IV) and subcutaneous (SC) administration of XmAb13676” NCT02924402 ↗ |
| Route | Subcutaneous | “intravenous (IV) and subcutaneous (SC) administration of XmAb13676” NCT02924402 ↗ |